Agilent said revenue for the quarter ended July 31, 2024 was $1.58 billion, down 5.6% from a year earlier (down 4.4% on a core basis), and GAAP net income was $282 million, or $0.97 per share.

1. 01

   Agilent said revenue for the quarter ended July 31, 2024 was $1.58 billion, down 5.6% from a year earlier (down 4.4% on a core basis), and GAAP net income was $282 million, or $0.97 per share.

2. 02

   The company disclosed that non-GAAP net income for Q3 was $385 million, or $1.32 per share, lower than $422 million, or $1.43 per share, a year earlier, and that its reconciling items to GAAP included restructuring and other related costs of 67 million.

3. 03

   The company reported segment revenue for Q3 of $782 million for Life Sciences and Applied Markets Group (operating margin of 28.4%), $411 million for Agilent CrossLab Group (34.0%), and $385 million for Diagnostics and Genomics Group (18.3%). Of the three segments, only Agilent CrossLab Group grew from the year-earlier period, rising 4%.

4. 04

   The company set full-year revenue guidance at $6.450 billion to $6.500 billion and full-year non-GAAP earnings per share guidance at $5.21 to $5.25. For Q4, it expects revenue of $1.641 billion to $1.691 billion and non-GAAP earnings per share of $1.38 to $1.42.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.